Previous 10 | Next 10 |
Agenus (AGEN) shares rise nearly 5% premarket after the company posted fourth-quarter results that beat Wall Street estimates, helped partly by upfront license fee gained from recent transactions.The company posted fourth-quarter revenue of $31.26M, that beat analysts' est...
Agenus (AGEN): Q4 GAAP EPS of -$0.20 beats by $0.02.Revenue of $31.26M (-9.4% Y/Y) beats by $15.03M.Press Release For further details see: Agenus EPS beats by $0.02, beats on revenue
Completion of balstilimab BLA filing on target for 1H 2021 New clinical data for AGEN1181 to be presented at AACR TIGIT bispecific AGEN1777 IND to be filed in 2Q 2021 iNKT cell therapy cancer trials to commence in 1H 2021 LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE)...
Clinical benefit in previously unresponsive tumors, including CRC, ovarian, and endometrial Confirmed responses in cold tumors as characterized by MSS No neuroendocrine toxicities or hypophysitis Registrational trials planned to commence in 2021 LEXINGTON, Mass., March 1...
LEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release...
Preliminary Phase 1 trial results show three of four intubated COVID-19 patients were discharged after treatment via AGEN's new iNKT cell-therapy. Incredibly, two were extubated within 24 hours of dosing. As frantic families around the world demand access to AGEN's iNKT cell therapy f...
Agenus (AGEN) appoints of Andy Hurley as its chief commercial officer.Andy brings three decades of international experience as a strategic commercial leader at large and small biopharmaceutical companies.He joins Agenus from his most recent role as the svenior ice president at ...
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appoint...
Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT” LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed t...
6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancers No complement-mediated toxicities reported LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoin...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...